Biotech faces a reckoning: ‘We've lost our luster in cell therapies’

Cell therapy has been slashed by a thousand cuts over the past few years, from the failure of autologous CAR-T to live up to expectations, to market challenges to manufacturing woes. And now, the focus has shifted to autoimmune conditions.

The biopharma industry is now facing a reckoning; Will the market ever fully accept these treatments?